Objective:

To reevaluate the pathology specimens of individuals who underwent surgery for non-small cell lung cancer, specifically examining how STAS and LVI influence recurrence rates and overall survival outcomes.

Key Findings:

• STAS was present in 59.1% of cases, with a higher prevalence in adenocarcinoma, indicating a significant correlation with poor prognosis.
• Age, lymph node invasion, stage, and STAS were statistically significant for survival outcomes, highlighting their importance in prognosis.
• LVI did not show a significant effect on survival, possibly due to uneven disease stage distribution, warranting further investigation.

Interpretation:

STAS is a significant independent prognostic factor in NSCLC, indicating a higher risk of recurrence and poorer survival outcomes, while LVI's impact may be overshadowed by other factors, suggesting a need for further clinical exploration.

Limitations:

• Retrospective design may introduce selection bias, potentially affecting the reliability of the findings.
• Exclusion of patients with prior cancer or distant metastasis limits generalizability and may overlook important prognostic factors.

Conclusion:

STAS should be considered in the pathological evaluation of NSCLC as it significantly impacts prognosis, while LVI's role may require further investigation to clarify its clinical relevance.